Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently joined Steve Darling from Proactive to discuss the company's collaboration with Bilthoven Biologicals (BBio) to advance TNX-801, Tonix’s promising vaccine candidate for mpox. TNX-801 is a live, replicating, attenuated virus vaccine based on horsepox, currently in preclinical development to prevent both mpox and smallpox.
TNX-801 leverages cutting-edge technology with the potential to serve as a viral vector platform, enabling the development of recombinant versions to protect against other infectious diseases. BBio, a global leader in vaccine production, was selected by the European Union for its pandemic preparedness program, making them an ideal partner for this collaboration.
Dr. Lederman shared that TNX-801 has shown remarkable results in preclinical studies, demonstrating immune protection in animal models with better tolerability compared to vaccines based on 20th-century vaccinia viruses. Specifically, TNX-801 has been shown to protect non-human primates against a lethal challenge with intratracheal Clade 1 monkeypox virus. Following a single-dose vaccination, the vaccine not only prevented clinical disease and lesions but also significantly decreased viral shedding in the mouth and lungs, suggesting strong mucosal immunity and the potential to block forward transmission.
This collaboration between Tonix Pharmaceuticals and BBio represents a significant step forward in the fight against mpox and smallpox, and the technology behind TNX-801 may pave the way for future vaccines against a range of infectious diseases.
#proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp
#ChronicPain #PharmaNews #MedicalResearch #DrugApproval #HealthcareInnovation #ProactiveInterviews
#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
13 сен 2024
